– USA, CA – Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, announced today that Mr. Kenneth R. Greathouse has been appointed to the Board of Directors.
“We are pleased to have Ken joining us at such an important stage for the Company,” commented John Walker, Chief Executive Officer and Chairman of the Board.
“Ken’s commercial experience in the field of neurology will provide Zosano with leadership and insight as we progress M207 towards the market.” “I am pleased to join the Board,” commented Mr. Greathouse. “I look forward to working with the management team and Board as our lead program progresses towards an NDA filing and, if approved, towards commercialization.”
Kenneth R. Greathouse is a seasoned pharmaceutical executive with over 40 years of experience in sales, marketing, business development and commercial operations. He is the co-founder of several successful drug development companies, including Manchester Pharmaceuticals which was sold to Retrophin Inc. in 2014. He began his career with Lederle Laboratories where for over 18 years he held a number of sales and marketing positions of increasing responsibility.
He joined Athena Neurosciences in 1993 and continued with Elan Pharmaceuticals after the acquisition of Athena. After a two year tenure at Boron LePore and Associates as Vice President and General Manager of Contract Sales, he joined Questcor as Senior Vice President, Commercial Operations. Since leaving Questcor, Mr. Greathouse has co-founded and served as CEO of Argent Development Group LLC, Melbourne Laboratories LLC, Valcrest Pharmaceuticals LLC, and Hesperian BioPharma LLC, in addition to Manchester Pharmaceuticals LLC.
About Zosano Pharma
Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray, or ADAM technology. The Company recently announced positive results from our ZOTRIP study that evaluated M207, which is our proprietary formulation of zolmitriptan delivered via our ADAM technology, as an acute treatment for migraine. Zosano is focused on developing products where rapid administration of established molecules with known safety and efficacy profiles provides an increased benefit to patients, for markets where patients remain underserved by existing therapies. The Company anticipates that many of its current and future development programs may enable the Company to utilize a regulatory pathway that would streamline clinical development and accelerate the path towards commercialization.
For more information : http://www.zosanopharma.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
